Search

Your search keyword '"Johnson-Chilla A"' showing total 22 results
Start Over Author "Johnson-Chilla A"
22 results on '"Johnson-Chilla A"'

1. NCCN Guidelines Insights: Rectal Cancer, Version 6.2020

Author

Wells A. Messersmith, Ignacio Garrido-Laguna, Dustin A. Deming, Aparna Raj Parikh, Alyse Johnson-Chilla, Alan P. Venook, Christopher G. Willett, Katrina S. Pedersen, Jeffrey A. Meyerhardt, Al B. Benson, Yi Jen Chen, Hitendra Patel, Mustafa A. Arain, Natalie Kirilcuk, Constantinos T. Sofocleous, David Shibata, Harry S. Cooper, Jean L. Grem, Mary F. Mulcahy, Steven J. Nurkin, Stacey Cohen, Smitha S. Krishnamurthi, Charles Schneider, Kristen K. Ciombor, Michael J. Overman, Andrew Gunn, John M. Skibber, Steven C. Hunt, Leonard Saltz, Lisa A. Gurski, Eden Stotsky-Himelfarb, Mahmoud M. Al-Hawary, Sarah E. Hoffe, Elena M. Stoffel, Eric D. Miller, and Joleen M. Hubbard

Subjects
0301 basic medicine, medicine.medical_specialty, Colorectal cancer, business.industry, General surgery, medicine.medical_treatment, MEDLINE, Treatment options, Sigmoid colon, Rectum, Disease, medicine.disease, digestive system diseases, BRAF V600E, 03 medical and health sciences, 030104 developmental biology, 0302 clinical medicine, medicine.anatomical_structure, Oncology, 030220 oncology & carcinogenesis, medicine, business, Neoadjuvant therapy
Abstract

The NCCN Guidelines for Rectal Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with rectal cancer. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines. These updates include clarifying the definition of rectum and differentiating the rectum from the sigmoid colon; the total neoadjuvant therapy approach for localized rectal cancer; and biomarker-targeted therapy for metastatic colorectal cancer, with a focus on new treatment options for patients with BRAF V600E– or HER2 amplification–positive disease.

Published
2020

2. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020

Author

Shailender Bhatia, Griselda Zuccarino-Catania, Suzanne McGettigan, Matthew A. Lunning, Jordan P. McPherson, Ryan M. Weight, Matthew J. Frigault, Jeffrey A. Sosman, Scott Shofer, John A. Thompson, Stephanie Andrews, Anita M. Engh, Nathan A. Pennell, Sunil Reddy, Nisha Mohindra, Alyse Johnson-Chilla, Jarushka Naidoo, Luciano J. Costa, Bryan J. Schneider, Sandip Pravin Patel, Marc S. Ernstoff, Lihua E. Budde, Philippe Armand, Marianne Davies, Yinghong Wang, Bianca Santomasso, Mabel Ryder, Benjamin H. Kaffenberger, Anthony J. Olszanski, Julie R. Brahmer, Olalekan O. Oluwole, and David Dunnington

Subjects
0301 basic medicine, medicine.medical_specialty, business.industry, medicine.medical_treatment, MEDLINE, Immunotherapy, Guideline, medicine.disease, Immune checkpoint, 03 medical and health sciences, Antineoplastic Agents, Immunological, 030104 developmental biology, 0302 clinical medicine, Oncology, Cancer immunotherapy, Neoplasms, 030220 oncology & carcinogenesis, Humans, Medicine, Colitis, business, Intensive care medicine, Adverse effect
Abstract

The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy. These NCCN Guidelines Insights describe symptoms that may be caused by an irAE and should trigger further investigation, and summarize the NCCN Management of Immunotherapy-Related Toxicities Panel discussions for the 2020 update to the guidelines regarding immune checkpoint inhibitor–related diarrhea/colitis and cardiovascular irAEs.

Published
2020

3. Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Author

Rahul Aggarwal, Alyse Johnson-Chilla, Darren R. Feldman, Bradley Alexander McGregor, William T. Lowrance, David Smith, Jennifer Keller, Chad A. LaGrange, David J. Vaughn, Daniel M. Geynisman, Lenora A. Pluchino, Daniel W. Lin, Katherine S. Tzou, Kosj Yamoah, Steven L. Hancock, Jonathan Yamzon, Philip J. Saylor, Timothy D Gilligan, Daniel A. Vaena, Kanishka Sircar, Phillip M. Pierorazio, Soroush Rais-Bahrami, Hamid Emamekhoo, Thomas A. Longo, Joel Picus, Ithaar Derweesh, Ellis G. Levine, David D. Chism, Paul Monk, and Nicholas G. Cost

Subjects
Male, Oncology, medicine.medical_specialty, Adult patients, business.industry, MEDLINE, Prognosis, medicine.disease, Combined Modality Therapy, Clinical Practice, Testicular Neoplasms, Internal medicine, Practice Guidelines as Topic, medicine, Humans, Neoplasm Metastasis, business, Testicular cancer, Selection (genetic algorithm)
Abstract

Testicular cancer is relatively uncommon and accounts for 50% of patients dying within 1 year of diagnosis. This selection from the NCCN Guidelines for Testicular Cancer focuses on recommendations for the management of adult patients with nonseminomatous GCTs.

Published
2019

4. Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology

Author

Mary F. Mulcahy, Natalie Kirilcuk, Michael J. Overman, Jeffrey A. Meyerhardt, John M. Skibber, Mustafa A. Arain, Charles Schneider, Joleen M. Hubbard, Ms Steven Nurkin Nurkin, Al B. Benson, Lisa A. Gurski, Kristen K. Ciombor, David Shibata, Dustin A. Deming, Stacey Cohen, Ahmed Kamel, Yi Jen Chen, Ignacio Garrido-Laguna, Aparna Raj Parikh, Alyse Johnson-Chilla, Jean L. Grem, Eric D. Miller, Leonard B. Saltz, Smitha S. Krishnamurthi, Harry S. Cooper, Sarah E. Hoffe, Eden Stotsky-Himelfarb, Hitendra Patel, Constantinos T. Sofocleous, Steven C. Hunt, Alan P. Venook, Christopher G. Willett, Kristina M. Gregory, Mahmoud M. Al-Hawary, Katrina S. Pedersen, Wells A. Messersmith, and Elena M. Stoffel

Subjects
medicine.medical_specialty, medicine.diagnostic_test, business.industry, Colorectal cancer, medicine.medical_treatment, General surgery, Disease, Malignancy, medicine.disease, Systemic therapy, Endoscopy, Radiation therapy, 03 medical and health sciences, 0302 clinical medicine, Oncology, 030220 oncology & carcinogenesis, Combined Modality Therapy, Medicine, 030211 gastroenterology & hepatology, business, Watchful waiting
Abstract

Small bowel adenocarcinoma (SBA) is a rare malignancy of the gastrointestinal tract that has increased in incidence across recent years. Often diagnosed at an advanced stage, outcomes for SBA are worse on average than for other related malignancies, including colorectal cancer. Due to the rarity of this disease, few studies have been done to direct optimal treatment, although recent data have shown that SBA responds to treatment differently than colorectal cancer, necessitating a separate approach to treatment. The NCCN Guidelines for Small Bowel Adenocarcinoma were created to establish an evidence-based standard of care for patients with SBA. These guidelines provide recommendations on the workup of suspected SBA, primary treatment options, adjuvant treatment, surveillance, and systemic therapy for metastatic disease. Additionally, principles of imaging and endoscopy, pathologic review, surgery, radiation therapy, and survivorship are described.

Published
2019

5. Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

Author

Lihua E. Budde, Philippe Armand, Bianca Santomasso, Marianne Davies, Shailender Bhatia, Christopher J. Hoimes, Jillian L. Scavone, Bryan J. Schneider, Brianna Hoffner, Jeffrey A. Sosman, Yinghong Wang, Nisha Mohindra, Jarushka Naidoo, Momen M. Wahidi, Mabel Ryder, Stephanie Andrews, Matthew J. Frigault, Marc S. Ernstoff, Olalekan O. Oluwole, Julie R. Brahmer, Alyse Johnson-Chilla, Sunil Reddy, Anthony J. Olszanski, Luciano J. Costa, Scott Shofer, John A. Thompson, Mario E. Lacouture, David Dunnington, Sandip Pravin Patel, Frederick L. Locke, and Matthew A. Lunning

Subjects
medicine.medical_specialty, business.industry, medicine.medical_treatment, MEDLINE, Cancer, Disease, Immunotherapy, medicine.disease, Patient advocacy, Oncology nursing, Oncology, Family medicine, Medicine, Disease management (health), business, Adverse effect
Abstract

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions and ASCO, consisting of medical and hematologic oncologists with expertise in a wide array of disease sites, and experts from the fields of dermatology, gastroenterology, neuro-oncology, nephrology, emergency medicine, cardiology, oncology nursing, and patient advocacy. Several panel representatives are members of the Society for Immunotherapy of Cancer (SITC). The initial version of the NCCN Guidelines was designed in general alignment with recommendations published by ASCO and SITC. The content featured in this issue is an excerpt of the recommendations for managing toxicity related to immune checkpoint blockade and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to chimeric antigen receptor T-cell therapy, visitNCCN.org.

Published
2019

6. NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018

Author

Alyse Johnson-Chilla, John A. Ridge, Megan R. Haymart, Rebecca S. Sippel, Thomas N. Wang, Robert C. Smallridge, Jason P. Hunt, Matthew D. Ringel, Glenda G. Callender, Christopher D. Raeburn, Lindsay Bischoff, Lisa A. Gurski, Fouad Kandeel, Christian Nasr, Cord Sturgeon, Karin G. Hoffmann, Dominick Lamonica, Naifa L. Busaidy, Andrei Iagaru, Richard J. Wong, Randall P. Scheri, Jatin P. Shah, Whitney S. Goldner, David R. Byrd, Carl K. Hoh, Paxton V. Dickson, Peter Kopp, Robert I. Haddad, Quan-Yang Duh, Lori J. Wirth, Bryan McIver, and Hormoz Ehya

Subjects
Image-Guided Biopsy, Proto-Oncogene Proteins B-raf, 0301 basic medicine, Oncology, endocrine system, medicine.medical_specialty, endocrine system diseases, Medullary cavity, medicine.medical_treatment, Treatment outcome, Thyroid Gland, Medical Oncology, medicine.disease_cause, Targeted therapy, Thyroid carcinoma, Anaplastic thyroid carcinoma, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, medicine, Humans, Thyroid Neoplasms, Protein Kinase Inhibitors, Societies, Medical, Thyroid neoplasm, Neoplasm Staging, Clinical Trials as Topic, business.industry, Carcinoma, Prognosis, United States, Treatment Outcome, 030104 developmental biology, 030220 oncology & carcinogenesis, Thyroidectomy, Neoplasm staging, business
Abstract

The NCCN Guidelines for Thyroid Carcinoma provide recommendations for the management of different types of thyroid carcinoma, including papillary, follicular, Hurthle cell, medullary, and anaplastic carcinomas. These NCCN Guidelines Insights summarize the panel discussion behind recent updates to the guidelines, including the expanding role of molecular testing for differentiated thyroid carcinoma, implications of the new pathologic diagnosis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features, and the addition of a new targeted therapy option for BRAF V600E-mutated anaplastic thyroid carcinoma.

Published
2018

7. NCCN Guidelines Insights: Rectal Cancer, Version 6.2020

Author

Al B, Benson, Alan P, Venook, Mahmoud M, Al-Hawary, Mustafa A, Arain, Yi-Jen, Chen, Kristen K, Ciombor, Stacey, Cohen, Harry S, Cooper, Dustin, Deming, Ignacio, Garrido-Laguna, Jean L, Grem, Andrew, Gunn, Sarah, Hoffe, Joleen, Hubbard, Steven, Hunt, Natalie, Kirilcuk, Smitha, Krishnamurthi, Wells A, Messersmith, Jeffrey, Meyerhardt, Eric D, Miller, Mary F, Mulcahy, Steven, Nurkin, Michael J, Overman, Aparna, Parikh, Hitendra, Patel, Katrina, Pedersen, Leonard, Saltz, Charles, Schneider, David, Shibata, John M, Skibber, Constantinos T, Sofocleous, Elena M, Stoffel, Eden, Stotsky-Himelfarb, Christopher G, Willett, Alyse, Johnson-Chilla, and Lisa A, Gurski

Subjects
Rectal Neoplasms, Colonic Neoplasms, Practice Guidelines as Topic, Humans, Neoadjuvant Therapy
Abstract

The NCCN Guidelines for Rectal Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with rectal cancer. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines. These updates include clarifying the definition of rectum and differentiating the rectum from the sigmoid colon; the total neoadjuvant therapy approach for localized rectal cancer; and biomarker-targeted therapy for metastatic colorectal cancer, with a focus on new treatment options for patients with BRAF V600E- or HER2 amplification-positive disease.

Published
2020

8. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

Author

Thomas W. Flaig, Philippe E. Spiess, Neeraj Agarwal, Rick Bangs, Stephen A. Boorjian, Mark K. Buyyounouski, Sam Chang, Tracy M. Downs, Jason A. Efstathiou, Terence Friedlander, Richard E. Greenberg, Khurshid A. Guru, Thomas Guzzo, Harry W. Herr, Jean Hoffman-Censits, Christopher Hoimes, Brant A. Inman, Masahito Jimbo, A. Karim Kader, Subodh M. Lele, Jeff Michalski, Jeffrey S. Montgomery, Lakshminarayanan Nandagopal, Lance C. Pagliaro, Sumanta K. Pal, Anthony Patterson, Elizabeth R. Plimack, Kamal S. Pohar, Mark A. Preston, Wade J. Sexton, Arlene O. Siefker-Radtke, Jonathan Tward, Jonathan L. Wright, Lisa A. Gurski, and Alyse Johnson-Chilla

Subjects
Male, Oncology, Urinary Bladder Neoplasms, Humans, Female, Medical Oncology
Abstract

This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on the clinical presentation and workup of suspected bladder cancer, treatment of non–muscle-invasive urothelial bladder cancer, and treatment of metastatic urothelial bladder cancer because important updates have recently been made to these sections. Some important updates include recommendations for optimal treatment of non–muscle-invasive bladder cancer in the event of a bacillus Calmette-Guérin (BCG) shortage and details about biomarker testing for advanced or metastatic disease. The systemic therapy recommendations for second-line or subsequent therapies have also been revised. Treatment and management of muscle-invasive, nonmetastatic disease is covered in the complete version of the NCCN Guidelines for Bladder Cancer available at NCCN.org. Additional topics covered in the complete version include treatment of nonurothelial histologies and recommendations for nonbladder urinary tract cancers such as upper tract urothelial carcinoma, urothelial carcinoma of the prostate, and primary carcinoma of the urethra.

Published
2020

9. Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Author

Jenna Rossoff, Kris M. Mahadeo, Lewis B. Silverman, Luke Maese, Carrie L. Kitko, Laura G. Schuettpelz, Ndiya Ogba, Hiroto Inaba, David T. Teachey, Gregory A. Yanik, Kenneth B. DeSantes, Susan Colace, Alyse Johnson-Chilla, Vilmarie Rodriguez, Mari Dallas, Victor W. Wong, Valentina Nardi, Patrick A. Brown, Norman J. Lacayo, Colleen Annesley, Weili Sun, Kara M. Kelly, Ronica Nanda, Jill C. Beck, Jessica Sun, and Nicole A. Larrier

Subjects
medicine.medical_specialty, Lymphoblastic Leukemia, medicine.medical_treatment, Organizations, Nonprofit, MEDLINE, Improved survival, Disease, Hematopoietic stem cell transplantation, Medical Oncology, Pediatric Acute Lymphoblastic Leukemia, Antineoplastic Combined Chemotherapy Protocols, Medicine, Humans, Transplantation, Homologous, Molecular Targeted Therapy, Intensive care medicine, Child, Evidence-Based Medicine, business.industry, Age Factors, Hematopoietic Stem Cell Transplantation, Infant, Precursor Cell Lymphoblastic Leukemia-Lymphoma, United States, Transplantation, Survival Rate, Treatment Outcome, Oncology, Drug Resistance, Neoplasm, Pharmacogenomics, Neoplasm Recurrence, Local, business, SEER Program
Abstract

Acute lymphoblastic leukemia (ALL) is the most common pediatric malignancy. Advancements in technology that enhance our understanding of the biology of the disease, risk-adapted therapy, and enhanced supportive care have contributed to improved survival rates. However, additional clinical management is needed to improve outcomes for patients classified as high risk at presentation (eg, T-ALL, infant ALL) and who experience relapse. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for pediatric ALL provide recommendations on the workup, diagnostic evaluation, and treatment of the disease, including guidance on supportive care, hematopoietic stem cell transplantation, and pharmacogenomics. This portion of the NCCN Guidelines focuses on the frontline and relapsed/refractory management of pediatric ALL.

Published
2020

10. NCCN Guidelines Insights: Rectal Cancer, Version 6.2020

Author

Benson, Al B., primary, Venook, Alan P., additional, Al-Hawary, Mahmoud M., additional, Arain, Mustafa A., additional, Chen, Yi-Jen, additional, Ciombor, Kristen K., additional, Cohen, Stacey, additional, Cooper, Harry S., additional, Deming, Dustin, additional, Garrido-Laguna, Ignacio, additional, Grem, Jean L., additional, Gunn, Andrew, additional, Hoffe, Sarah, additional, Hubbard, Joleen, additional, Hunt, Steven, additional, Kirilcuk, Natalie, additional, Krishnamurthi, Smitha, additional, Messersmith, Wells A., additional, Meyerhardt, Jeffrey, additional, Miller, Eric D., additional, Mulcahy, Mary F., additional, Nurkin, Steven, additional, Overman, Michael J., additional, Parikh, Aparna, additional, Patel, Hitendra, additional, Pedersen, Katrina, additional, Saltz, Leonard, additional, Schneider, Charles, additional, Shibata, David, additional, Skibber, John M., additional, Sofocleous, Constantinos T., additional, Stoffel, Elena M., additional, Stotsky-Himelfarb, Eden, additional, Willett, Christopher G., additional, Johnson-Chilla, Alyse, additional, and Gurski, Lisa A., additional

Published
2020
Full Text
View/download PDF

11. NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020

Author

Thompson, John A., primary, Schneider, Bryan J., additional, Brahmer, Julie, additional, Andrews, Stephanie, additional, Armand, Philippe, additional, Bhatia, Shailender, additional, Budde, Lihua E., additional, Costa, Luciano, additional, Davies, Marianne, additional, Dunnington, David, additional, Ernstoff, Marc S., additional, Frigault, Matthew, additional, Kaffenberger, Benjamin H., additional, Lunning, Matthew, additional, McGettigan, Suzanne, additional, McPherson, Jordan, additional, Mohindra, Nisha A., additional, Naidoo, Jarushka, additional, Olszanski, Anthony J., additional, Oluwole, Olalekan, additional, Patel, Sandip P., additional, Pennell, Nathan, additional, Reddy, Sunil, additional, Ryder, Mabel, additional, Santomasso, Bianca, additional, Shofer, Scott, additional, Sosman, Jeffrey A., additional, Wang, Yinghong, additional, Weight, Ryan M., additional, Johnson-Chilla, Alyse, additional, Zuccarino-Catania, Griselda, additional, and Engh, Anita, additional

Published
2020
Full Text
View/download PDF

12. Bladder Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology

Author

Flaig, Thomas W., primary, Spiess, Philippe E., additional, Agarwal, Neeraj, additional, Bangs, Rick, additional, Boorjian, Stephen A., additional, Buyyounouski, Mark K., additional, Chang, Sam, additional, Downs, Tracy M., additional, Efstathiou, Jason A., additional, Friedlander, Terence, additional, Greenberg, Richard E., additional, Guru, Khurshid A., additional, Guzzo, Thomas, additional, Herr, Harry W., additional, Hoffman-Censits, Jean, additional, Hoimes, Christopher, additional, Inman, Brant A., additional, Jimbo, Masahito, additional, Kader, A. Karim, additional, Lele, Subodh M., additional, Michalski, Jeff, additional, Montgomery, Jeffrey S., additional, Nandagopal, Lakshminarayanan, additional, Pagliaro, Lance C., additional, Pal, Sumanta K., additional, Patterson, Anthony, additional, Plimack, Elizabeth R., additional, Pohar, Kamal S., additional, Preston, Mark A., additional, Sexton, Wade J., additional, Siefker-Radtke, Arlene O., additional, Tward, Jonathan, additional, Wright, Jonathan L., additional, Gurski, Lisa A., additional, and Johnson-Chilla, Alyse, additional

Published
2020
Full Text
View/download PDF

13. Pediatric Acute Lymphoblastic Leukemia, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Author

Brown, Patrick, primary, Inaba, Hiroto, additional, Annesley, Colleen, additional, Beck, Jill, additional, Colace, Susan, additional, Dallas, Mari, additional, DeSantes, Kenneth, additional, Kelly, Kara, additional, Kitko, Carrie, additional, Lacayo, Norman, additional, Larrier, Nicole, additional, Maese, Luke, additional, Mahadeo, Kris, additional, Nanda, Ronica, additional, Nardi, Valentina, additional, Rodriguez, Vilmarie, additional, Rossoff, Jenna, additional, Schuettpelz, Laura, additional, Silverman, Lewis, additional, Sun, Jessica, additional, Sun, Weili, additional, Teachey, David, additional, Wong, Victor, additional, Yanik, Gregory, additional, Johnson-Chilla, Alyse, additional, and Ogba, Ndiya, additional

Published
2020
Full Text
View/download PDF

14. Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Author

Gilligan, Timothy, primary, Lin, Daniel W., additional, Aggarwal, Rahul, additional, Chism, David, additional, Cost, Nicholas, additional, Derweesh, Ithaar H., additional, Emamekhoo, Hamid, additional, Feldman, Darren R., additional, Geynisman, Daniel M., additional, Hancock, Steven L., additional, LaGrange, Chad, additional, Levine, Ellis G., additional, Longo, Thomas, additional, Lowrance, Will, additional, McGregor, Bradley, additional, Monk, Paul, additional, Picus, Joel, additional, Pierorazio, Phillip, additional, Rais-Bahrami, Soroush, additional, Saylor, Philip, additional, Sircar, Kanishka, additional, Smith, David C., additional, Tzou, Katherine, additional, Vaena, Daniel, additional, Vaughn, David, additional, Yamoah, Kosj, additional, Yamzon, Jonathan, additional, Johnson-Chilla, Alyse, additional, Keller, Jennifer, additional, and Pluchino, Lenora A., additional

Published
2019
Full Text
View/download PDF

15. Small Bowel Adenocarcinoma, Version 1.2020

Author

Benson, Al B., Venook, Alan P., Al-Hawary, Mahmoud M., Arain, Mustafa A., Chen, Yi-Jen, Ciombor, Kristen K., Cohen, Stacey A., Cooper, Harry S., Deming, Dustin A., Garrido-Laguna, Ignacio, Grem, Jean L., Hoffe, Sarah E., Hubbard, Joleen, Hunt, Steven, Kamel, Ahmed, Kirilcuk, Natalie, Krishnamurthi, Smitha, Messersmith, Wells A., Meyerhardt, Jeffrey, Miller, Eric D., Mulcah, Mary F., Nurkin, Steven, Overman, Michael J., Parikh, Aparna, Patel, Hitendra, Pedersen, Katrina S., Saltz, Leonard B., Schneider, Charles, Shibata, David, Skibber, John M., Sofocleous, Constantinos T., Stoffel, Elena M., Stotsky-Himelfarb, Eden, Willett, Christopher G., Johnson-Chilla, Alyse, Gregory, Kristina M., and Gurski, Lisa A.

Subjects
Diagnosis, Differential, Treatment Outcome, Risk Factors, Intestinal Neoplasms, Intestine, Small, Practice Guidelines as Topic, Humans, Survivorship, Adenocarcinoma, Watchful Waiting, Combined Modality Therapy, Article, Neoplasm Staging
Abstract

Small bowel adenocarcinoma (SBA) is a rare malignancy of the gastrointestinal tract that has increased in incidence across recent years. Often diagnosed at an advanced stage, outcomes for SBA are worse on average than for other related malignancies, including colorectal cancer. Due to the rarity of this disease, few studies have been done to direct optimal treatment, although recent data have shown that SBA responds to treatment differently than colorectal cancer, necessitating a separate approach to treatment. The NCCN Guidelines for Small Bowel Adenocarcinoma were created to establish an evidence-based standard of care for patients with SBA. These guidelines provide recommendations on the workup of suspected SBA, primary treatment options, adjuvant treatment, surveillance, and systemic therapy for metastatic disease. Additionally, principles of imaging and endoscopy, pathologic review, surgery, radiation therapy, and survivorship are described.

Published
2019

16. Management of Immunotherapy-Related Toxicities, Version 1.2019

Author

John A, Thompson, Bryan J, Schneider, Julie, Brahmer, Stephanie, Andrews, Philippe, Armand, Shailender, Bhatia, Lihua E, Budde, Luciano, Costa, Marianne, Davies, David, Dunnington, Marc S, Ernstoff, Matthew, Frigault, Brianna, Hoffner, Christopher J, Hoimes, Mario, Lacouture, Frederick, Locke, Matthew, Lunning, Nisha A, Mohindra, Jarushka, Naidoo, Anthony J, Olszanski, Olalekan, Oluwole, Sandip P, Patel, Sunil, Reddy, Mabel, Ryder, Bianca, Santomasso, Scott, Shofer, Jeffrey A, Sosman, Momen, Wahidi, Yinghong, Wang, Alyse, Johnson-Chilla, and Jillian L, Scavone

Subjects
Antineoplastic Agents, Immunological, Drug-Related Side Effects and Adverse Reactions, Neoplasms, Disease Management, Humans, Molecular Targeted Therapy
Abstract

The aim of the NCCN Guidelines for Management of Immunotherapy-Related Toxicities is to provide guidance on the management of immune-related adverse events resulting from cancer immunotherapy. The NCCN Management of Immunotherapy-Related Toxicities Panel is an interdisciplinary group of representatives from NCCN Member Institutions and ASCO, consisting of medical and hematologic oncologists with expertise in a wide array of disease sites, and experts from the fields of dermatology, gastroenterology, neuro-oncology, nephrology, emergency medicine, cardiology, oncology nursing, and patient advocacy. Several panel representatives are members of the Society for Immunotherapy of Cancer (SITC). The initial version of the NCCN Guidelines was designed in general alignment with recommendations published by ASCO and SITC. The content featured in this issue is an excerpt of the recommendations for managing toxicity related to immune checkpoint blockade and a review of existing evidence. For the full version of the NCCN Guidelines, including recommendations for managing toxicities related to chimeric antigen receptor T-cell therapy, visit NCCN.org.

Published
2019

17. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018

Author

Masahito Jimbo, Richard E. Greenberg, Sumanta K. Pal, Subodh M. Lele, Jason A. Efstathiou, Anthony L. Patterson, Neeraj Agarwal, Harry W. Herr, Christopher J. Hoimes, Mary A. Dwyer, Joshua J. Meeks, Kamal S. Pohar, Tracy M. Downs, Mark K. Buyyounouski, Lisa A. Gurski, Lance C. Pagliaro, Daniel P. Petrylak, Jeffrey S. Montgomery, Jonathan D. Tward, Elizabeth R. Plimack, Jeff M. Michalski, A. Karim Kader, Wade J. Sexton, Michael P. Porter, Thomas W. Flaig, Alyse Johnson-Chilla, Geoffrey Wile, Arlene O. Siefker-Radtke, Philippe E. Spiess, Terence W. Friedlander, Khurshid A. Guru, Stephen A. Boorjian, Noah M. Hahn, Brant A. Inman, Mark A. Preston, and Rick Bangs

Subjects
Oncology, medicine.medical_specialty, Immune checkpoint inhibitors, medicine.medical_treatment, 030232 urology & nephrology, Locally advanced, Aftercare, Disease, Cystectomy, Medical Oncology, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Societies, Medical, Cancer staging, Neoplasm Staging, Randomized Controlled Trials as Topic, Bladder cancer, business.industry, Patient Selection, Treatment options, medicine.disease, Neoadjuvant Therapy, United States, Clinical Practice, Radiation therapy, Administration, Intravesical, Treatment Outcome, Urinary Bladder Neoplasms, Chemotherapy, Adjuvant, 030220 oncology & carcinogenesis, Lymphatic Metastasis, BCG Vaccine, Quality of Life, Radiotherapy, Adjuvant, business, Organ Sparing Treatments
Abstract

The NCCN Clinical Practice Guidelines in Oncology for Bladder Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up of patients with bladder cancer. These NCCN Guidelines Insights discuss important updates to the 2018 version of the guidelines, including implications of the 8th edition of the AJCC Cancer Staging Manual on treatment of muscle-invasive bladder cancer and incorporating newly approved immune checkpoint inhibitor therapies into treatment options for patients with locally advanced or metastatic disease.

Published
2018

18. NCCN Guidelines Insights: Multiple Myeloma, Version 1.2020

Author

Kumar, Shaji K., primary, Callander, Natalie S., additional, Hillengass, Jens, additional, Liedtke, Michaela, additional, Baljevic, Muhamed, additional, Campagnaro, Erica, additional, Castillo, Jorge J., additional, Chandler, Jason C., additional, Cornell, Robert F., additional, Costello, Caitlin, additional, Efebera, Yvonne, additional, Faiman, Matthew, additional, Garfall, Alfred, additional, Godby, Kelly, additional, Holmberg, Leona, additional, Htut, Myo, additional, Huff, Carol Ann, additional, Kang, Yubin, additional, Landgren, Ola, additional, Malek, Ehsan, additional, Martin, Thomas, additional, Omel, James, additional, Raje, Noopur, additional, Sborov, Douglas, additional, Singhal, Seema, additional, Stockerl-Goldstein, Keith, additional, Tan, Carlyn, additional, Weber, Donna, additional, Johnson-Chilla, Alyse, additional, Keller, Jennifer, additional, and Kumar, Rashmi, additional

Published
2019
Full Text
View/download PDF

19. Small Bowel Adenocarcinoma, Version 1.2020, NCCN Clinical Practice Guidelines in Oncology

Author

Benson, Al B., primary, Venook, Alan P., additional, Al-Hawary, Mahmoud M., additional, Arain, Mustafa A., additional, Chen, Yi-Jen, additional, Ciombor, Kristen K., additional, Cohen, Stacey A., additional, Cooper, Harry S., additional, Deming, Dustin A., additional, Garrido-Laguna, Ignacio, additional, Grem, Jean L., additional, Hoffe, Sarah E., additional, Hubbard, Joleen, additional, Hunt, Steven, additional, Kamel, Ahmed, additional, Kirilcuk, Natalie, additional, Krishnamurthi, Smitha, additional, Messersmith, Wells A., additional, Meyerhardt, Jeffrey, additional, Miller, Eric D., additional, Mulcahy, Mary F., additional, Nurkin, Steven, additional, Overman, Michael J., additional, Parikh, Aparna, additional, Patel, Hitendra, additional, Pedersen, Katrina S., additional, Saltz, Leonard B., additional, Schneider, Charles, additional, Shibata, David, additional, Skibber, John M., additional, Sofocleous, Constantinos T., additional, Stoffel, Elena M., additional, Stotsky-Himelfarb, Eden, additional, Willett, Christopher G., additional, Johnson-Chilla, Alyse, additional, Gregory, Kristina M., additional, and Gurski, Lisa A., additional

Published
2019
Full Text
View/download PDF

20. Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology

Author

Thompson, John A., primary, Schneider, Bryan J., additional, Brahmer, Julie, additional, Andrews, Stephanie, additional, Armand, Philippe, additional, Bhatia, Shailender, additional, Budde, Lihua E., additional, Costa, Luciano, additional, Davies, Marianne, additional, Dunnington, David, additional, Ernstoff, Marc S., additional, Frigault, Matthew, additional, Hoffner, Brianna, additional, Hoimes, Christopher J., additional, Lacouture, Mario, additional, Locke, Frederick, additional, Lunning, Matthew, additional, Mohindra, Nisha A., additional, Naidoo, Jarushka, additional, Olszanski, Anthony J., additional, Oluwole, Olalekan, additional, Patel, Sandip P., additional, Reddy, Sunil, additional, Ryder, Mabel, additional, Santomasso, Bianca, additional, Shofer, Scott, additional, Sosman, Jeffrey A., additional, Wahidi, Momen, additional, Wang, Yinghong, additional, Johnson-Chilla, Alyse, additional, and Scavone, Jillian L., additional

Published
2019
Full Text
View/download PDF

21. NCCN Guidelines Insights: Thyroid Carcinoma, Version 2.2018

Author

Haddad, Robert I., primary, Nasr, Christian, additional, Bischoff, Lindsay, additional, Busaidy, Naifa Lamki, additional, Byrd, David, additional, Callender, Glenda, additional, Dickson, Paxton, additional, Duh, Quan-Yang, additional, Ehya, Hormoz, additional, Goldner, Whitney, additional, Haymart, Megan, additional, Hoh, Carl, additional, Hunt, Jason P., additional, Iagaru, Andrei, additional, Kandeel, Fouad, additional, Kopp, Peter, additional, Lamonica, Dominick M., additional, McIver, Bryan, additional, Raeburn, Christopher D., additional, Ridge, John A., additional, Ringel, Matthew D., additional, Scheri, Randall P., additional, Shah, Jatin P., additional, Sippel, Rebecca, additional, Smallridge, Robert C., additional, Sturgeon, Cord, additional, Wang, Thomas N., additional, Wirth, Lori J., additional, Wong, Richard J., additional, Johnson-Chilla, Alyse, additional, Hoffmann, Karin G., additional, and Gurski, Lisa A., additional

Published
2018
Full Text
View/download PDF

22. NCCN Guidelines Insights: Bladder Cancer, Version 5.2018

Author

Flaig, Thomas W., primary, Spiess, Philippe E., additional, Agarwal, Neeraj, additional, Bangs, Rick, additional, Boorjian, Stephen A., additional, Buyyounouski, Mark K., additional, Downs, Tracy M., additional, Efstathiou, Jason A., additional, Friedlander, Terence, additional, Greenberg, Richard E., additional, Guru, Khurshid A., additional, Hahn, Noah, additional, Herr, Harry W., additional, Hoimes, Christopher, additional, Inman, Brant A., additional, Jimbo, Masahito, additional, Kader, A. Karim, additional, Lele, Subodh M., additional, Meeks, Joshua J., additional, Michalski, Jeff, additional, Montgomery, Jeffrey S., additional, Pagliaro, Lance C., additional, Pal, Sumanta K., additional, Patterson, Anthony, additional, Petrylak, Daniel P., additional, Plimack, Elizabeth R., additional, Pohar, Kamal S., additional, Porter, Michael P., additional, Preston, Mark A., additional, Sexton, Wade J., additional, Siefker-Radtke, Arlene O., additional, Tward, Jonathan, additional, Wile, Geoffrey, additional, Johnson-Chilla, Alyse, additional, Dwyer, Mary A., additional, and Gurski, Lisa A., additional

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results